Compared with the control IgG, the anti-HBc mAb significantly reduced the fold increase of circulating HBsAg level at 14 days and 70 days post antibody treatment (Figure 9C), suggesting that the anti-HBc IgG response at the early phase of infection contributed to reduce the long-term burden of HBV infection. The gene discussed is KRT88P; the disease is infection.